Advances in 3D-Printed Microfluidic Platforms for Drug Discovery, Diagnostics, and Personalized Medicine

Abstract

Three-dimensional (3D) printed microfluidic chips have emerged as versatile platforms for miniaturized pharmaceutical analysis, enabling precise manipulation of microliter to nanoliter volumes within integrated lab-on-a-chip architectures. This review summarizes the evolution of microfabrication from conventional silicon and glass photolithography to polymer-based soft lithography and, more recently, additive manufacturing approaches that provide rapid prototyping, reduced cost, and enhanced geometric complexity. Key printing technologies, including stereolithography, digital light processing, fused deposition modelling, and multi-material jetting, are discussed with respect to resolution, materials, and suitability for biomedical applications. Design considerations, computational modeling, fabrication strategies, and post-processing methods are highlighted to optimize channel performance, mixing efficiency, and device reliability. The integration of optical and electrochemical sensors, real-time detection systems, and artificial intelligence-driven data analytics is examined for high-throughput drug screening, pharmacokinetic studies, toxicity assessment, and point-of-care diagnostics. Validation methodologies, regulatory requirements, and technical challenges such as surface roughness, cytotoxicity, and scalability are critically evaluated. Collectively, 3D-printed microfluidics offers flexible, cost-effective, and physiologically relevant platforms that bridge laboratory research and clinical translation, positioning additive manufacturing as a transformative technology for next-generation pharmaceutical development and personalized medicine across diverse healthcare settings worldwide.